Javier Perales-Patón

Javier Perales-Patón

Auto-generated profile, based on publicly available information

Javier Perales-Patón

Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2020 in Nature
Verified
Journal Article
Closed access
PDF file
CKChristoph Kuppe
Christoph Kuppe
MIMahmoud M. Ibrahim
Mahmoud M. Ibrahim
JKJennifer Kranz
Jennifer Kranz
XZXiaoting Zhang
Xiaoting Zhang
SZSusanne Ziegler
Susanne Ziegler
RKRafael Kramann
Rafael Kramann

12 February 2020 in Genome Biology
Verified
Journal Article
Open access
PDF file
CHChristian Holland
Christian Holland
JTJovan Tanevski
Jovan Tanevski
JPJavier Perales-Patón
Javier Perales-Patón
JGJan Gleixner
Jan Gleixner
MKManu P. Kumar
Manu P. Kumar
JSJulio Saez-Rodriguez
Julio Saez-Rodriguez
Background: Many functional analysis tools have been developed to extract functional and mechanistic insight from bulk transcriptome data. With the advent of single-cell RNA sequencing (scRNA-seq), it is in principle possible to do such an analysis for single cells. However, scRNA-seq data has characteristics such as drop-out events and low library sizes. It is thus not clear if functional TF and pathway analysis tools established for bulk sequencing can be applied to scRNA-seq in a meaningful way.Results: To address this question, we perform benchmark studies on simulated and real scRNA-seq data. We include the bulk-RNA tools PROGENy, GO enrichment, and DoRothEA that estimate pathway and transcription factor (TF) activities, respectively, and compare them against the tools SCENIC/AUCell and metaVIPER, designed for scRNA-seq. For the in silico study, we simulate single cells from TF/pathway perturbation bulk RNA-seq experiments. We complement the simulated data with real scRNA-seq data upon CRISPR-mediated knock-out. Our benchmarks on simulated and real data reveal comparable performance to the original bulk data. Additionally, we show that the TF and pathway activities preserve cell type-specific variability by analyzing a mixture sample sequenced with 13 scRNA-seq protocols. We also provide the benchmark data for further use by the community.Conclusions: Our analyses suggest that bulk-based functional analysis tools that use manually curated footprint gene sets can be applied to scRNA-seq data, partially outperforming dedicated single-cell tools. Furthermore, we find that the performance of functional analysis tools is more sensitive to the gene sets than to the statistic used.

1 April 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SEShannon Elf
Shannon Elf
NANouran S. Abdelfattah
Nouran S. Abdelfattah
ECEdwin Chen
Edwin Chen
JPJavier Perales-Patón
Javier Perales-Patón
EREmily A. Rosen
Emily A. Rosen
AMAnn Mullally
Ann Mullally
Somatic mutations in calreticulin (CALR) are present in approximately 40% of patients with myeloproliferative neoplasms (MPN), but the mechanism by which mutant CALR is oncogenic remains unclear. Here, we demonstrate that expression of mutant CALR alone is sufficient to engender MPN in mice and recapitulates the disease phenotype of patients with CALR-mutant MPN. We further show that the thrombopoietin receptor MPL is required for mutant CALR-driven transformation through JAK–STAT pathway activation, thus rendering mutant CALR-transformed hematopoietic cells sensitive to JAK2 inhibition. Finally, we demonstrate that the oncogenicity of mutant CALR is dependent on the positive electrostatic charge of the C-terminus of the mutant protein, which is necessary for physical interaction between mutant CALR and MPL. Together, our findings elucidate a novel paradigm of cancer pathogenesis and reveal how CALR mutations induce MPN. Significance: The mechanism by which CALR mutations induce MPN remains unknown. In this report, we show that the positive charge of the CALR mutant C-terminus is necessary to transform hematopoietic cells by enabling binding between mutant CALR and the thrombopoietin receptor MPL. Cancer Discov; 6(4); 368–81. ©2016 AACR. See related commentary by Stanley and Steidl, p. 344. This article is highlighted in the In This Issue feature, p. 331

1 April 2019 in Cancer Cell
Verified
Journal Article
Closed access
MBMaría Teresa Blasco
María Teresa Blasco
CNCarolina Navas
Carolina Navas
GMGuillermo Martín-Serrano
Guillermo Martín-Serrano
OGOsvaldo Graña-Castro
Osvaldo Graña-Castro
CLCarmen G. Lechuga
Carmen G. Lechuga
MBMariano Barbacid
Mariano Barbacid

30 September 2015 in Cancer Research
Verified
Journal Article
Closed access
PDF file
GRGarcilaso Riesco-Eizaguirre
Garcilaso Riesco-Eizaguirre
LWLeón Wert-Lamas
León Wert-Lamas
JPJavier Perales-Patón
Javier Perales-Patón
ASAna Sastre-Perona
Ana Sastre-Perona
LFLara P. Fernández
Lara P. Fernández
PSPIlar Santisteban
PIlar Santisteban
The presence of differentiated thyroid cells in thyroid cancer is critical for the antitumor response to radioactive iodide treatment, and loss of the differentiated phenotype is a key hallmark of iodide-refractory metastatic disease. The role of microRNAs (miRNA) in fine-tuning gene expression has become a major regulatory mechanism by which developmental and pathologic processes occur. In this study, we performed next-generation sequencing and expression analysis of eight papillary thyroid carcinomas (PTC) to comprehensively characterize miRNAs involved in loss of differentiation. We found that only a small set of abundant miRNAs is differentially expressed between PTC tissue and normal tissue from the same patient. In addition, we integrated computational prediction of potential targets and mRNA sequencing and identified a master miRNA regulatory network involved in essential biologic processes such as thyroid differentiation. Both mature products of mir-146b (miR-146b-5p and -3p) were among the most abundantly expressed miRNAs in tumors. Specifically, we found that miR-146b-3p binds to the 3′-untranslated region of PAX8 and sodium/iodide symporter (NIS), leading to impaired protein translation and a subsequent reduction in iodide uptake. Furthermore, our findings show that miR-146b and PAX8 regulate each other and share common target genes, thus highlighting a novel regulatory circuit that governs the differentiated phenotype of PTC. In conclusion, our study has uncovered the existence of a miR-146b-3p/PAX8/NIS regulatory circuit that may be exploited therapeutically to modulate thyroid cell differentiation and iodide uptake for improved treatment of advanced thyroid cancer. Cancer Res; 75(19); 4119–30. ©2015 AACR.

24 April 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LVLy P Vu
Ly P Vu
CPCamila Prieto
Camila Prieto
EAElianna M Amin
Elianna M Amin
SCSagar Chhangawala
Sagar Chhangawala
AKAndrei Krivtsov
Andrei Krivtsov
MKMichael G Kharas
Michael G Kharas
The identity of the RNA-binding proteins (RBPs) that govern cancer stem cells remains poorly characterized. The MSI2 RBP is a central regulator of translation of cancer stem cell programs. Through proteomic analysis of the MSI2-interacting RBP network and functional shRNA screening, we identified 24 genes required for in vivo leukemia. Syncrip was the most differentially required gene between normal and myeloid leukemia cells. SYNCRIP depletion increased apoptosis and differentiation while delaying leukemogenesis. Gene expression profiling of SYNCRIP-depleted cells demonstrated a loss of the MLL and HOXA9 leukemia stem cell program. SYNCRIP and MSI2 interact indirectly though shared mRNA targets. SYNCRIP maintains HOXA9 translation, and MSI2 or HOXA9 overexpression rescued the effects of SYNCRIP depletion. Altogether, our data identify SYNCRIP as a new RBP that controls the myeloid leukemia stem cell program. We propose that targeting these RBP complexes might provide a novel therapeutic strategy in leukemia.